Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

Rhea-AI Summary

Zentalis Pharmaceuticals (NASDAQ: ZNTL) has announced the acceptance of an abstract for poster presentation at the 2025 ASCO Annual Meeting in Chicago from May 30 to June 3, 2025. The presentation will showcase clinical data from their ongoing Phase 1/2 trial of azenosertib, their WEE1 inhibitor, in combination with encorafenib and cetuximab for treating patients with metastatic BRAF V600E mutant colorectal cancer.

The poster presentation, titled 'Phase 1 dose escalation results of the WEE1 inhibitor, azenosertib,' will be presented by Dr. Jeanne Tie on Saturday, May 31, 2025, from 9:00 a.m. to 12:00 p.m. CDT. The data cutoff date for the presentation is April 4, 2025. The poster will be available on the Zentalis website under the 'Supporting Publications' tab in the 'Our Approach' section.

Positive

• Potential first-in-class and best-in-class WEE1 inhibitor development
• Progress in Phase 1/2 clinical trial with data ready for presentation

Negative

• None.

News Market Reaction

+0.67%

1 alert

+0.67% News Effect

On the day this news was published, ZNTL gained 0.67%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Zentalis^® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that an abstract has been accepted for poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3, 2025 in Chicago, IL.

The poster will include clinical data as of an April 4, 2025 data cutoff from the Company’s ongoing Phase 1/2 clinical trial evaluating azenosertib in combination with encorafenib and cetuximab in patients with metastatic BRAF V600E mutant colorectal cancer.

Abstract and poster presentation details are below:

Title: “Phase 1 dose escalation results of the WEE1 inhibitor, azenosertib, in combination with encorafenib and cetuximab in patients with previously treated BRAF V600E mutant metastatic colorectal cancer”
Abstract Number: 3551
Poster Session: Gastrointestinal Cancer – Colorectal and Anal
Poster Board: 372
Date/Time: Saturday, May 31, 2025, 9:00 a.m. - 12:00 p.m. CDT
Presenter: Dr. Jeanne Tie

The poster can be accessed through the “Supporting Publications” tab on the “Our Approach” section of the Zentalis website on the day of the presentation.

About Azenosertib

Azenosertib is a novel, selective, and orally bioavailable inhibitor of WEE1 currently being evaluated as a monotherapy and combination clinical studies in ovarian cancer and additional tumor types. WEE1 acts as a master regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. By inhibiting WEE1, azenosertib enables cell cycle progression, despite high levels of DNA damage, thereby resulting in the accumulation of DNA damage and leading to mitotic catastrophe and cancer cell death.

About Zentalis Pharmaceuticals

Zentalis^® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.

For more information, please visit www.zentalis.com. Follow Zentalis on X/Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.

ZENTALIS^® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release. 

Contact: 
Haibo Wang - Chief Business Officer
Ron Moldaver - Investor Relations
ir@zentalis.com  

FAQ

What clinical trial data will Zentalis (ZNTL) present at ASCO 2025?

Zentalis will present Phase 1/2 clinical trial data for azenosertib combined with encorafenib and cetuximab in patients with metastatic BRAF V600E mutant colorectal cancer.

When and where will Zentalis (ZNTL) present their ASCO 2025 poster?

The poster will be presented on May 31, 2025, from 9:00 a.m. to 12:00 p.m. CDT at the ASCO Annual Meeting in Chicago.

What is the potential market position of Zentalis (ZNTL) azenosertib?

Azenosertib is being developed as a potentially first-in-class and best-in-class WEE1 inhibitor for ovarian cancer and other tumor types.

What is the target patient population for Zentalis (ZNTL) azenosertib trial?

The trial targets patients with previously treated BRAF V600E mutant metastatic colorectal cancer.